Mounjaro, the weight loss medication which is 50% better than Wegovy
With ongoing delays to the launch of Wegovy in the UK, attention is now turning to the next “big thing” in weight management medication: Mounjaro by Eli Lilly, a medication which gives even better results than Wegovy
50% more effective than Wegovy
In the world of pharmaceutical advancements, the name Mounjaro has emerged as a beacon of hope for those striving to achieve sustainable weight loss. Developed by Eli Lilly, the US pharmaceutical company, Mounjaro carries the promise of transforming lives by addressing a challenge that millions of individuals around the globe face - obesity.
Let's delve into the world of Mounjaro, the commercial name for the groundbreaking medication Tirzepatide, and explore its potential to revolutionize weight loss journeys.
Obesity, a complex health concern, has long been associated with a myriad of health risks, including cardiovascular diseases, diabetes, and more. Recognizing the urgency to combat this epidemic, pharmaceutical research has been focused on developing innovative solutions. Tirzepatide, the active ingredient in Mounjaro, has garnered attention due to its impressive potential to not only manage blood sugar levels but also induce significant weight loss.
Clinical trials have unveiled the remarkable effectiveness of Tirzepatide in promoting weight loss. In a recent Phase 3 clinical trial named SURPASS-2, participants experienced awe-inspiring results. Tirzepatide demonstrated its ability to lead to substantial weight reduction compared to a placebo. Individuals on Tirzepatide exhibited an average weight loss of 23% over 68 weeks, demonstrating the medication’s potential to be a game-changer in the field of weight management.
That level of weight loss is significantly greater than the weight loss with Wegovy, the commercial name for semaglutide. In the STEP clinical trials, Wegovy resulted in weight loss of about 15% after a year, which implies that Mounjaro is about 50% more effective as a means of losing weight.
Double action benefit
What sets Tirzepatide apart is its unique mechanism of action. Unlike Wegovy which is classed as GLP-1 medication, Mounjaro adds a second factor, GIP, to give a double benefit.
This combined GLP-1 and GIP receptor agonist works by regulating the body's appetite and metabolism, leading to reduced calorie intake and increased energy expenditure. Its dual action on two key hormones - GLP-1 and GIP - provides a multifaceted approach to weight loss, making it a promising option for those struggling with obesity.
Moreover, Mounjaro's potential benefits extend beyond weight loss. Clinical trials have also demonstrated improvements in metabolic parameters such as blood sugar control and lipid profiles. This holistic approach makes Tirzepatide a valuable contender not just for weight management but for overall metabolic health enhancement.
Take as part of a full weight management service
It's important to note that while the results from clinical trials are promising, individual responses to Tirzepatide may vary. As with any medication, consultation with a healthcare professional is paramount before initiating any treatment plan and for best results, it should be taken as part of full weight management service comprising dietitian support, physical activity advice, psychological support where necessary, and regular health coach appointments.
As the horizon of healthcare continues to evolve, Mounjaro emerges as a symbol of progress, bringing us closer to a healthier and happier world.
Published: 10 August 2023